Aeterna Zentaris Inc

NASDAQ:AEZSUnited StatesView on Canadian Exchange

Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The Company is engaged in the development of its therapeutic asset and has established a pre-clinical development pipeline to potentially address unmet medical needs across a number of indications, including neuromyelitis optica spectrum disorder (NMOSD), Parkinson's disease (PD), hypoparathyroidism and amyotrophic lateral sclerosis (ALS). Its therapeutic development pipeline includes AIM Biologicals, AEZS-150 and AEZS-130.

Contact Information

Headquarters

315 Sigma DriveSUMMERVILLE, NB, Canada 29486

Phone

418-652-8525

Fax

418-948-9191

Executives

Non-Executive Independent Chairman of the Board

Carolyn Egbert

Managing Director - AEZS Germany

Klaus Paulini

Chief Financial Officer, Senior Vice President

Giuliano La Fratta

Senior Vice President - Non-Clinical Development, Chief Scientific Officer

Michael Teifel

Senior Vice President - Clinical Development, Chief Medical Officer

Nicola Ammer